Cognition Therapeutics, Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
CGTX Nasdaq 2834 www.cogrx.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Cognition Therapeutics, Inc.

Cognition Therapeutics Extends Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies - Feb 5th, 2026 5:30 am
Cognition Therapeutics Completes Type C Meeting with FDA for Zervimesine (CT1812) in Dementia with Lewy Bodies - Jan 27th, 2026 5:30 am
Cognition Therapeutics Publishes Phase 2 Clinical Results Showing Zervimesine’s Potential to Slow the Progression of Dementia with Lewy Bodies - Jan 6th, 2026 5:30 am
Will Cognition Therapeutics (NASDAQ:CGTX) Spend Its Cash Wisely? - Dec 5th, 2025 7:46 am
Cognition Therapeutics Reaches Full Enrollment in Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies - Dec 3rd, 2025 5:30 am
Cognition Therapeutics Presents Phase 3 Plan for Zervimesine (CT1812) in Alzheimer’s Disease at Clinical Trials on Alzheimer’s Disease (CTAD) Conference - Dec 1st, 2025 5:30 am
Cognition Therapeutics to Participate in 37th Annual Piper Sandler Healthcare Conference - Nov 20th, 2025 2:01 pm
Cognition Therapeutics Completes Enrollment in Phase 2 Study of Zervimesine (CT1812) in Early Alzheimer’s Disease - Nov 13th, 2025 5:36 am
Cognition Therapeutics Reports Financial Results for the Third Quarter 2025 and Highlights Progress Across Clinical Programs - Nov 6th, 2025 5:30 am
Has ANI Pharmaceuticals (ANIP) Outpaced Other Medical Stocks This Year? - Oct 27th, 2025 7:40 am
Cognition Therapeutics (CGTX) Moves to Buy: Rationale Behind the Upgrade - Oct 8th, 2025 10:00 am
Cognition Therapeutics Study of Zervimesine (CT1812) in Early Alzheimer’s Disease Reaches 75% Enrollment Target - Sep 3rd, 2025 5:30 am
Cognition Therapeutics Closes $30 Million Registered Direct Offering to Two New Fundamental Institutional Investors, Including a Preeminent Global Investment Firm to Support Phase 3 Development of Zervimesine (CT1812) - Sep 2nd, 2025 2:00 pm
Cognition Therapeutics Announces $30 Million Registered Direct Offering of Common Stock - Aug 27th, 2025 6:53 pm
Cognition Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement - Aug 26th, 2025 2:00 pm
Cognition Therapeutics Receives End-of-Phase 2 Meeting Minutes Confirming Alignment with U.S. FDA on Registrational Path for Zervimesine (CT1812) in Alzheimer’s Disease - Aug 12th, 2025 2:00 pm
Cognition Therapeutics Reports Financial Results for the Second Quarter 2025 and Highlights Progress Across Clinical Programs - Aug 7th, 2025 2:00 pm
Cognition Therapeutics Presents Data at AAIC Highlighting Broad Neurological Impact of Zervimesine (CT1812) in Dementia with Lewy Bodies and Alzheimer’s Disease - Jul 29th, 2025 5:30 am
Cognition Therapeutics Publishes Proteomic Analysis Elucidating Zervimesine’s Protection of Neurons and Synapses in Alzheimer’s Disease - Jul 21st, 2025 5:30 am
Cognition Therapeutics' Positive Clinical Data from Zervimesine (CT1812) Phase 2 Study in Dementia with Lewy Bodies (DLB) will be Presented in a Podium Presentation at AAIC - Jul 16th, 2025 5:30 am